top of page
N2B
Treatment of Parkinson’s-related Depression
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
N2B | Biotechnology & Biopharmaceutical | 01/01/2015 | "1-10" |
N2B Ltd is developing an intranasal delivery formulation of the approved drug Rasagiline for the treatment of depression associated with Parkinson’s disease (PD). The company is on a quick regulatory pathway for NDA submission through the U.S. FDA 5O5(b)(2) approach.
N2B’s preclinical results indicate that intranasal delivery of Rasagiline could provide both a useful alternative to oral administration in the treatment of PD and a novel therapeutic approach for the treatment of depression in PD patients.
N2B was founded as an incubator company of Youdim Pharmaceuticals.
bottom of page